OPK vs. LXRX, ADCT, AVIR, XOMA, INVA, RIGL, VNDA, MACK, MNKD, and LGND
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Lexicon Pharmaceuticals (LXRX), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), XOMA (XOMA), Innoviva (INVA), Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), Merrimack Pharmaceuticals (MACK), MannKind (MNKD), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry.
OPKO Health (NASDAQ:OPK) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
OPKO Health received 31 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 65.69% of users gave OPKO Health an outperform vote while only 64.94% of users gave Lexicon Pharmaceuticals an outperform vote.
Lexicon Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
OPKO Health has a net margin of -21.76% compared to Lexicon Pharmaceuticals' net margin of -14,573.20%. OPKO Health's return on equity of -12.69% beat Lexicon Pharmaceuticals' return on equity.
OPKO Health has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
In the previous week, OPKO Health had 12 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 17 mentions for OPKO Health and 5 mentions for Lexicon Pharmaceuticals. OPKO Health's average media sentiment score of 0.56 beat Lexicon Pharmaceuticals' score of 0.51 indicating that OPKO Health is being referred to more favorably in the media.
OPKO Health presently has a consensus price target of $3.73, indicating a potential upside of 248.13%. Lexicon Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 128.31%. Given OPKO Health's higher probable upside, analysts clearly believe OPKO Health is more favorable than Lexicon Pharmaceuticals.
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 47.3% of OPKO Health shares are held by insiders. Comparatively, 6.8% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
OPKO Health beats Lexicon Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
OPKO Health Competitors List
Related Companies and Tools